85X0 Stock Chart & Stats
€0.17
-€0.03(-9.58%)
At close: 4:00 PM EST
€0.17
-€0.03(-9.58%)
Day’s Range― - ―
52-Week Range€0.15 - €0.34
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.83M
Enterprise Value€117.21
Total Cash (Recent Filing)€3.93M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 21, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding47,601,730
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.23
Price to Sales (P/S)146.53
P/FCF Ratio-4.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€212.79K
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet (no Debt)Zero reported debt materially reduces refinancing and interest-rate risk for a small biotech. That structural conservatism preserves financial optionality during multi-year product development cycles, enabling the firm to prioritize commercialization or strategic partnerships without near-term debt service constraints.
Focus On Microbial-derived Bio-based IngredientsA core business centered on fermentation-produced bio-based materials targets durable secular demand for sustainable ingredients across food, cosmetics, and industrial markets. This product focus supports repeatable B2B sales, potential scale economies in fermentation, and alignment with long-term sustainability-driven purchasing trends.
Reported Strong Revenue Growth MetricA reported ~45% revenue growth rate signals early commercial traction versus the prior base. While absolute revenue is small and volatile, sustained double-digit growth over multiple periods would indicate improving product-market fit and the potential to leverage fixed fermentation costs into higher margins as volumes scale.
Bears Say
Negative Gross Profit And Persistent LossesRepeated negative gross profit indicates the core production economics currently lose money, not just elevated overhead. Structurally unprofitable unit economics undermine long-term scalability: without sustained positive gross margins the business cannot self-fund growth or deliver durable operating profits as volumes expand.
Consistent Negative Operating And Free Cash FlowOngoing negative OCF and FCF, with accelerated cash burn in 2025, create a structural funding requirement. Reliance on external capital raises dilution and execution risk, constraining long-term R&D and scale-up investments and increasing the probability management must prioritize short-term financing over strategic initiatives.
Declining Equity And Capital ErosionFalling equity signals capital erosion from persistent losses, reducing the firm's balance-sheet cushion to absorb setbacks. Over the medium term this heightens the risk of dilutive recapitalizations or constrained investment capacity, weakening the company's ability to execute commercialization at scale without adverse shareholder impacts.
85X0 FAQ
What was Bioextrax AB’s price range in the past 12 months?
Bioextrax AB lowest stock price was €0.15 and its highest was €0.34 in the past 12 months.
What is Bioextrax AB’s market cap?
Bioextrax AB’s market cap is €10.83M.
When is Bioextrax AB’s upcoming earnings report date?
Bioextrax AB’s upcoming earnings report date is Aug 21, 2026 which is in 19 days.
How were Bioextrax AB’s earnings last quarter?
Bioextrax AB released its earnings results on May 20, 2026. The company reported -€0.008 earnings per share for the quarter, beating the consensus estimate of -€0.009 by <€0.001.
Is Bioextrax AB overvalued?
According to Wall Street analysts Bioextrax AB’s price is currently Overvalued.
Does Bioextrax AB pay dividends?
Bioextrax AB does not currently pay dividends.
What is Bioextrax AB’s EPS estimate?
Bioextrax AB’s EPS estimate is >-0.01.
How many shares outstanding does Bioextrax AB have?
Bioextrax AB has 47,601,730 shares outstanding.
What happened to Bioextrax AB’s price movement after its last earnings report?
Bioextrax AB reported an EPS of -€0.008 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went up 10.502%.
Which hedge fund is a major shareholder of Bioextrax AB?
Currently, no hedge funds are holding shares in DE:85X0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioextrax AB
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.
Technical Analysis
Scandinavian Enviro Systems AB
―
Axolot Solutions Holding AB
―
Nordic LEVEL Group AB Class B
―
CirChem AB
―
Clemondo Group AB
―